2,2-dimethyl-2H-pyrano<3,2-b>pyridine | 118066-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: 2,2-dimethyl-2H-pyrano<3,2-b>pyridine
• 英文别名: 2,2-Dimethylpyrano[3,2-b]pyridine
• CAS: 118066-94-7
• 化学式: C₁₀H₁₁NO
• mdl: MFCD18802971
• 分子量: 161.203
• InChiKey: RDWMRGMSNHAKBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-2H-pyrano<3,2-b>pyridine 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 水 、 sodium hydride 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 25.0h， 生成 1-((3R,4S)-3-Hydroxy-2,2-dimethyl-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-pyrrolidin-2-one
  参考文献：
  名称：

  Variation in the aromatic ring of cromakalim: antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans

  摘要：

  The synthesis and antihypertensive activity in the spontaneously hypertensive rat of two new series of analogues related to cromakalim (1) are described. In the first series, where the benzopyran nucleus has been replaced by a pyranopyridine nucleus, the position of the nitrogen atom has been found to be critical for activity, and the most potent compounds are the pyrano[3,2-c]pyridines. In the second series, where the powerful electron-withdrawing cyano group of compound 1 has been replaced by alkyl and phenyl groups, the order of antihypertensive potency is ethyl, isopropyl, tert-butyl greater than propyl, cyclopentyl greater than methyl greater than phenyl.

  DOI：

  10.1021/jm00173a018
• 作为产物：
  描述：

  3-(1,1-Dimethyl-prop-2-ynyloxy)-pyridine 以 邻二氯苯 为溶剂， 生成 2,2-dimethyl-2H-pyrano<3,2-b>pyridine
  参考文献：
  名称：

  Evans, John M.; Stemp, Geoffrey, Synthetic Communications, 1988, vol. 18, # 10, p. 1111 - 1118

  摘要：

  DOI：

文献信息

• SUBSTITUTED PYRROLO[2,3-D] PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：SANOFI

  公开号：EP4105218A1

  公开（公告）日：2022-12-21

  Disclosed are compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. Also disclosed are methods of using such compounds as inhibitors of LRRK2, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating neurodegenerative diseases such as Parkinson's disease,

  公开了式 (I) 的化合物或其药学上可接受的盐，其中 R1 和 R2 在本文中定义。还公开了使用此类化合物作为 LRRK2 抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗神经退行性疾病，如帕金森病、
• Cotterill, W. David; Johnson, David A.; Livingstone, Robert, Journal of Chemical Research, Miniprint, 1995, # 1, p. 221 - 243
  作者：Cotterill, W. David、Johnson, David A.、Livingstone, Robert

  DOI：——

  日期：——
• Cotterill, W. David; Johnston, David A.; Livingstone, Robert, Journal of Chemical Research, Miniprint, 1995, # 6, p. 1466 - 1476
  作者：Cotterill, W. David、Johnston, David A.、Livingstone, Robert

  DOI：——

  日期：——
• BURRELL, GORDON;CASSIDY, FREDERICK;EVANS, JOHN M.;LIGHTOWLER, DIANE;STEMP+, J. MED. CHEM., 33,(1990) N1, C. 3023-3027
  作者：BURRELL, GORDON、CASSIDY, FREDERICK、EVANS, JOHN M.、LIGHTOWLER, DIANE、STEMP+

  DOI：——

  日期：——
• Cotterill David, Johnson David A., Livingstone Robert, J. Chem. Res. Synop, (1995) N 1, S 12-13
  作者：Cotterill David, Johnson David A., Livingstone Robert

  DOI：——

  日期：——